22 results about "Vinblastine" patented technology

The invention relates to the technical field of biological medicine, in particular to application of a creatine related gene detection reagent in preparation of breast cancer prognosis products. The creatine related gene is an IGFBP1 gene and / or a TBC1D4 gene. According to the method, the expression levels of IGFBP1 and TBC1D4 genes in breast cancer patient samples are detected, a risk score is calculated by using a random survival forest (RSF) model, and the one-year, two-year and three-year survival rates of breast cancer patients are accurately predicted according to the risk score result. Meanwhile, the invention proves that IGFBP1 and TBC1D4 genes can be used as potential targets for breast cancer treatment, the IGFBP1 and fulvestrant as well as the TBC1D4 and vinblastine have stable binding capacity, and a new basis is provided for selection of individualized treatment medicines for breast cancer.

The invention discloses a strawberry FaLEC2 gene and application thereof, and relates to the field of plant molecular biology, the nucleotide sequence of the FaLEC2 gene is as shown in SEQ ID NO.1, and the amino acid sequence of protein encoded by the strawberry FaLEC2 gene is as shown in SEQ ID NO.2. The invention studies the application of the FaLEC2 gene in regulating and controlling the contents of vinblastine, 3-deoxy-D-mann-2-octanone acid, raspberry glycoside and linolenic acid in strawberries. It is found that through overexpression of the FaLEC2 gene, the content of vinblastine, the content of 3-deoxy-D-mann-2-octanone acid, the content of raspberry glycoside and the content of linolenic acid in the strawberries can be increased; the metabolism regulation and control mechanism of the vinblastine, the 3-deoxy-D-mann-2-octanone acid, the raspberry glycoside and the linolenic acid in the strawberry fruits can be further known, so that the content of the vinblastine, the 3-deoxy-D-mann-2-octanone acid, the raspberry glycoside and the linolenic acid in the strawberry fruits can be regulated and controlled by utilizing a biotechnological means; an important foundation is laid for strawberry variety improvement.

The present invention provides a method for manufacturing a drug-coated balloon and a drug-coated balloon obtained by the method. The method for manufacturing a drug-coated balloon is used to apply a drug coating on the surface of a balloon body prepared in advance and in a filled and expanded state, and the anti-proliferative drug component in the drug coating is one or more of nimustine, carmustine, 5-fluorouracil, fluguanosine, gemcitabine, daunorubicin, doxorubicin, paclitaxel, vinblastine, topotecan, aminoglutethimide, sirolimus, everolimus, and zotarolimus. The drug-coated balloon prepared by the method can effectively ensure that when the balloon enters the human body, the thickness of the drug coating on the balloon surface is more uniform and consistent, thereby improving the clinical use effect.

The application discloses a Catharanthus roseus EIN3-EILs transcription factor and application thereof, relates to the field of biotechnology, and the nucleotide sequence of the transcription factor CrEIN3 is shown as SEQ ID NO:1, and the protein coding sequence is shown as SEQ ID NO:2. The overexpression method is as follows: cloning the Catharanthus roseus CrEIN3 gene; constructing an overexpression vector; obtaining an agrobacterium engineering strain through agrobacterium mediation; and transiently transforming the Catharanthus roseus petals. The Catharanthus roseus EIN3-EILs transcription factor CrEIN3 is applied to increasing the content of vinblastine in the Catharanthus roseus. Through transient overexpression of CrEIN3 in the Catharanthus roseus petals, the synthesis of vinblastine in the Catharanthus roseus petals can be remarkably improved, and this has important significance for efficient production of vinblastine in the Catharanthus roseus.

The application discloses a vinblastine synthase, an encoding gene thereof and an application, and belongs to the technical field of genetic engineering. By using transcriptome data of Vinca minor, a 2OGD enzyme, namely, vinblastine synthase Vm15G000668, is screened and obtained, and in-vitro purification finds that the vinblastine synthase Vm15G000668 can specifically catalyze conversion of longchun dimethylbiguanide into vinblastine, and a key catalytic step of vinblastine biosynthesis is analyzed. The application provides a high-efficiency and specific vinblastine synthetic biocatalyst, and provides technical support for large-scale and green preparation of vinblastine.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention belongs to the technical field of karyotype analysis of chromosomes, and particularly relates to a cell pretreatment solution for karyotype analysis and preparation of chromosomes and application of the cell pretreatment solution. The cell pretreatment solution comprises the following components: 15 mmol / L Hepes buffer solution with the pH value of 7.2-7.6, 0.08-1.2 [mu] g / mL of vinblastine, 0.1-0.5 v / v% of Triton X-100 and 1-2 mmol / L of EDTA (Ethylene Diamine Tetraacetic Acid), and is a cell pretreatment solution with low toxicity, better dyeing effect and good cell type universality. When the cell pretreatment liquid is used for preparing a chromosome specimen, the preparation time is remarkably shortened, not only can more metaphase cell division phases be obtained, but also the proportion of the division phases capable of being used for chromosome analysis is greater than 83%, and the efficiency of karyotype analysis is remarkably improved. Meanwhile, the prepared chromosome specimen is clear in structure number, good in form, high in dispersity and few in background impurities, and the accuracy of chromosome karyotype analysis is remarkably improved.

A compound as shown in general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and the use thereof in cancer-related diseases such as acute myeloid leukemia. The synthesized vinblastine derivative has an antiproliferative activity against acute myeloid leukemia cancer cells that is significantly superior to that of vinblastine, can be used as a toxin molecule in the development of antibody-drug conjugates, and has a great anti-tumor effect.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

Disclosed is a method for treating a condition, which includes the steps of: selecting a patient for treatment who has the condition; administering to the patient at least one active pharmaceutical ingredient (API); and administering to the patient at least one metal complex represented by formula (I):including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof. Also disclosed is a composition for conducting the method, which includes: at least one API selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir; and at least one metal complex effective to potentiate an efficacy of the API to treat the condition, wherein the at least one metal complex is represented by formula (I), including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof.

The application discloses a method for improving vinblastine content in Catharanthus roseus based on EIN3 / EILs transcription factor CrEIL1 and a method for determining the vinblastine content. According to the method, the CrEIL1 gene of the Catharanthus roseus is cloned, a pLB-CrEIL1 plasmid vector is constructed, the CrEIL1 overexpression vector is constructed by using the pLB-CrEIL1 plasmid vector, and the CrEIL1 overexpression vector is used to mediate the overexpression of CrEIL1 in the Catharanthus roseus by means of Agrobacterium tumefaciens, so that the vinblastine yield in the Catharanthus roseus can be improved at low cost, in an environment-friendly and reliable manner.

The invention discloses a method for increasing the content of vinblastine in catharanthus roseus based on an EIN3 / EILs transcription factor CrEIL1 and a method for measuring the content of the vinblastine. The method comprises the following steps: cloning a Catharanthus roseus CrEIL1 gene, constructing a pLB-CrEIL1 plasmid vector, constructing a CrEIL1 overexpression vector by using the pLB-CrEIL1 plasmid vector, using the CrEIL1 overexpression vector, and performing agrobacterium tumefaciens-mediated overexpression of CrEIL1 in Catharanthus roseus, so that the yield of vinblastine in Catharanthus roseus can be increased in a low-cost, environment-friendly and reliable manner.

The invention discloses application of vincamine in preparation of a medicine for treating testis ischemia-reperfusion injury. Research results show that vincamine can significantly improve the pathological structure of the testis, alleviate inflammatory response and oxidative stress injury, and inhibit pyroptosis of testis cells, so that the reproductive function of the testis is protected after testis torsion reduction; the action mechanism is that an NF-kappa B signal channel is inhibited by up-regulating GPR40. The invention provides a novel potential drug for testis ischemia reperfusion injury.

The invention discloses a catharanthus roseus EIN3-EILs transcription factor and application thereof, and relates to the technical field of biology, the nucleotide sequence of the transcription factor CrEIN3 is shown as SEQ ID NO: 1, and the protein coding sequence is shown as SEQ ID NO: 2; the overexpression method comprises the following steps: cloning a catharanthus roseus CrEIN3 gene; constructing an overexpression vector; through agrobacterium tumefaciens mediation, an agrobacterium tumefaciens engineering strain is obtained; and instantaneously converting the Catharanthus roseus petals. The Catharanthus roseus EIN3-EILs transcription factor CrEIN3 is applied to increase of the content of vinblastine in Catharanthus roseus. The CrEIN3 is instantly overexpressed in the catharanthus roseus petals, so that the synthesis of the vinblastine in the catharanthus roseus petals can be remarkably improved, and the method has important significance for efficiently producing the vinblastine in the catharanthus roseus.

The invention provides an exosome composition for reducing side effects of chemotherapy treatment and a preparation method of the exosome composition, and belongs to the technical field of medicines. The preparation method comprises the following steps: preparing a co-crystal from methotrexate, vinblastine and daunorubicin, loading the co-crystal on UiO-66-NH2 grafted with RGD, loading the co-crystal on exosome, embedding the UiO-66-NH2 and the exosome in a compound of acrylic acid, traditional Chinese medicine polysaccharide and pullulan to prepare a slow-release long-half-life exosome system, and uniformly mixing the slow-release long-half-life exosome system with D-ribose, yeast-beta glucan and glutathione to prepare a sustained-release long-half-life exosome. The traditional Chinese medicine polysaccharide is obtained by carrying out boiling water extraction and ethanol precipitation on codonopsis pilosula, angelica sinensis, polygonatum kingianum and dendrobium officinale kimura et migo. The exosome composition for reducing the side effects of chemotherapy is prepared, the drug resistance of tumor cells is reduced, the drug effect is improved, the side effects after chemotherapy are reduced, the effect of targeted slow release of drugs is achieved, and the exosome composition has wide application prospects.

The invention provides an insecticide for fagaceae plant seeds as well as a preparation method and application thereof, and relates to the technical field of seed insecticides. The insecticide disclosed by the invention is prepared by mixing, crushing and granulating raw materials, wherein the raw materials comprise 70-85 wt.% of effective components and 15-30 wt.% of auxiliaries. The neonicotinoid insecticide is used as a main ingredient, vinblastine is used as a synergist, the insecticidal and insect prevention effects of the insecticide are effectively improved, the dosage of the insecticide is reduced, and the risk that fagaceae plant seeds are damaged by worms is effectively reduced and prevented. The insecticide for the fagaceae plant seeds is efficient, low in toxicity, environmentally friendly and easy to prepare, and has remarkable technical advantages and good application prospects.

The invention provides an anti-CCR9 antibody molecule for use in a method of treatment of cancer in a mammalian subject wherein the anti-CCR9 antibody molecule is administered simultaneously, sequentially or separately with a chemotherapeutic agent selected from the group consisting of: vincristine, docetaxel, paclitaxel, nanoparticle albumin-bound paclitaxel, and vinblastine, wherein said anti-CCR9 antibody molecule and said chemotherapeutic agent are not conjugated together. Also provided are related methods of treatment.

A method for making a sulfur cathode, comprising steps oF mixing sulfur and an amount of a purine compound in a weight ratio of sulfur to purine of from less than 10:1 to greater than 2:1 to form a powder mixture; mixing the powder mixture with a solvent to form a slurry; and drying the slurry onto a current collector to form the sulfur cathode. A cathode for use in a lithium sulfur battery including sulfur; and an purine selected from the group consisting of caffeine, nicotine, morphine, codeine, quinine, atropine, ephedrine, strychnine, colchicine, theobromine, theophylline, papaverine, reserpine, coniine, harmine, ibogaine, vinblastine, vincristine, yohimbine, capsaicin, camptothecin, mitragynine, apomorphine, psilocybin, scopolamine, tetrahydrocannabinol (THC), salvinorin A, mescaline, muscarine, preferably, the purine is caffeine. Also disclosed are electrolytes and batteries.

Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include temozolomide, lenalidomide, Oxaliplatin, Cisplatin, Carboplatin, 5-fluorouracil, irinotecan, topotecan, cyclophosphamide, doxorubicin, vincristine, vinblastine, Melphalan, Chlorambucil, Dacarbazine, Daunorubicin, Epirubicin, Mitoxantrone, Etoposide, Teniposide, Azacitidine, Cytarabine, Gemcitabine, vinoralbine, Pemetrexed, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral suspension. Other embodiments are directed towards methods of using and methods of making such formulations.

The invention relates to a compound shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate of the compound, and application of the compound in cancer-related diseases such as acute myelogenous leukemia. The anti-proliferative activity of the synthesized vinblastine derivative on acute myelogenous leukemia cancer cells is obviously superior to that of vinblastine, and the vinblastine derivative can be used as a toxin molecule for development of antibody coupling drugs and has a very good anti-tumor effect. # imgabs0 #

The application provides an exosome composition for reducing side effects of chemotherapy treatment and a preparation method thereof, and belongs to the technical field of medicines. Methotrexate, vinblastine and daunorubicin are prepared into a co-crystal, loaded on UiO-66-NH2 connected with RGD, loaded on exosomes, and embedded in an acrylic acid, traditional Chinese medicine polysaccharide and pullulan compound to obtain a sustained-release high half-life exosome system, which is uniformly mixed with D-ribose, yeast-beta glucan and glutathione to obtain the exosome composition for reducing side effects of chemotherapy treatment. The traditional Chinese medicine polysaccharide is traditional Chinese medicine polysaccharide obtained by boiling water extraction and ethanol precipitation of radix codonopsis, angelica, polygonatum sibiricum and dendrobium officinale. The exosome composition for reducing side effects of chemotherapy treatment is prepared, drug resistance of tumor cells is reduced, drug efficacy is improved, side reactions after chemotherapy are reduced, the effect of targeted slow release of drugs is achieved, and the exosome composition has a wide application prospect.